Related Experiment Video
Updated: Jul 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Genomics and the second golden era of cancer drug development
1Cancer Research UK Centre for Cancer Therapeutics, Sutton, UK. paul.workman@icr.ac.uk
Abstract:
The first golden era of cancer drug development was initiated in the 1940s and gave rise to the cytotoxic agents that dominate current cancer medicine. The second golden era is now underway in which cancer genomics will direct drug development.
Insights
The first era of cancer drug development yielded cytotoxic agents. The current, second golden era utilizes cancer genomics to guide new drug discovery and development.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- The 1940s marked the first golden era of cancer drug development, introducing cytotoxic agents.
- Cytotoxic agents remain the cornerstone of contemporary cancer chemotherapy.
- A paradigm shift is occurring in cancer treatment strategies.
Purpose of the Study:
- To highlight the historical progression of cancer drug development.
- To introduce the concept of a "second golden era" driven by genomics.
- To emphasize the transformative potential of cancer genomics in directing future drug discovery.
Main Methods:
- Historical analysis of cancer drug development milestones.
- Review of current cancer treatment modalities.
- Exploration of the role of genomic data in precision medicine.
Main Results:
- The initial era produced broadly acting cytotoxic drugs.
- The current era is characterized by a shift towards targeted therapies.
- Genomic insights are increasingly informing the development of novel cancer therapeutics.
Conclusions:
- Cancer genomics represents a new frontier in oncology drug development.
- Personalized medicine approaches are becoming central to cancer care.
- The integration of genomics promises more effective and tailored cancer treatments.
More Related Videos
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

